SeaStar Medical Expands QUELIMMUNE to Fifth Hospital

Introduction

SeaStar Medical Holding Corp (NASDAQ: ICU) is a commercial-stage medical device company focused on cell-directed extracorporeal therapies for critically ill patients. Its patented Selective Cytopheretic Device (SCD) integrates with standard continuous renal replacement therapy (CRRT) to modulate hyperinflammation by targeting activated neutrophils and monocytes. In 2024, the U.S. Food and Drug Administration approved the company’s first product, QUELIMMUNE (SCD-PED), for pediatric acute kidney injury (AKI) due to sepsis.

Corporate Structure

Founded in 2018, SeaStar Medical operates with a lean team of approximately 2–10 employees. Leadership includes CEO Eric Schlorff and Senior Vice President Tim Varacek (Commercial & Business Operations). Key scientific contributions stem from Dr. David Humes, whose research underpins the SCD technology. The company maintains partnerships with academic centers such as the University of Michigan and collaborates on government-funded trials.

Recent Developments and News

• January 27, 2025: SeaStar shipped QUELIMMUNE to its fifth hospital customer, a California pediatric research center, marking expansion to five commercial sites.
• January 31, 2025: The company announced a $6 million at-the-market registered direct offering—3,529,412 shares (or pre-funded warrants) plus detachable warrants—priced at $1.70 per share, expected to close on February 3, 2025.
• June 20, 2025: A Form S-1 registration statement (File No. 333-288065) became effective, allowing for future securities offerings under that shelf registration.
• June 23, 2025: The company filed a preliminary prospectus (Rule 424(b)(4)) for a $0.65-per-share offering of 4,935,385 common shares, accompanied by Series A and B warrants, and 1,218,462 pre-funded warrants, targeting approximately $3.68 million in proceeds before expenses.
• Ongoing: A pivotal adult AKI trial is underway, with SCD therapy having received FDA Breakthrough Device Designation in six indications, including adult AKI and cardiorenal syndrome.

Financial and Strategic Analysis

On June 25, 2025, ICU closed at $0.4710, up 30.98% on 20.7 million shares traded. As of June 20, 2025, the 52-week range stood at $0.31 (low on June 20, 2025) to $13.85 (high on July 9, 2024). Key metrics (TTM): revenue $428,000; net margin –3,716%; EBITDA $17.7 million; debt/equity 64.3%. The market capitalization is approximately $7.8 million with 16.14 million shares outstanding and a year-to-date change of –77.1%.

SeaStar is leveraging capital raises to fund the commercialization of QUELIMMUNE in pediatrics and advance adult trials. The at-market offering and 424B4 prospectus reflect an effort to improve liquidity and support operations, including institutional review board approvals at additional hospitals. The absence of minimum offering amounts presents fundraising risks, and potential dilution may arise from warrants and pre-funded warrants.

Market Position and Industry Context

SeaStar operates in the niche of extracorporeal immunomodulation, a sub-segment of medical device manufacturing. There are currently no FDA-approved therapies specifically targeting cytokine storms in CRRT settings, making the SCD platform address a crucial unmet need among ICU patients with AKI, sepsis, or multi-organ dysfunction. QUELIMMUNE’s Humanitarian Device Exemption status in pediatrics provides a distinct market position. Ongoing Breakthrough Device designations assist in facilitating an accelerated regulatory pathway and may lead to favorable reimbursement conditions. Competitive pressures are currently moderate, though commercial success will rely on expanding hospital adoption and validating clinical benefits in adult populations.

TL;DR

ICU shares increased by 30.98% to $0.4710 on June 25, 2025, following SEC filings for a $0.65-per-share common stock and warrant offering and the effectiveness of a June shelf registration. In January, SeaStar reported expansion with its fifth hospital for QUELIMMUNE and announced a $6 million at-the-market financing. A pivotal adult AKI trial is ongoing and is supported by six FDA Breakthrough Device designations. Future catalysts include additional hospital IRB approvals, adult trial data, and the completion of ongoing capital raises.